Terence Ketter

Clinical Focus

• Psychiatry
• Bipolar Disorder
• Psychopharmacology

Administrative Appointments

• Chief, Bipolar Disorders Clinic (1995 - present)

Honors and Awards

• Distinguished Fellow, American Psychiatric Association (2006)
• Independent Investigator Award, National Alliance for Research in Schizophrenia and Depression (2003-2005)
• Outstanding Faculty Physician Award, Vaden Health Center, Stanford University (2002)
• Independent Investigator Award, National Alliance for Research in Schizophrenia and Depression (1999-2001)
• Independent Investigator Award, Stanley Foundation Research Award Program (1996-2000)

Professional Education

Postdoctoral Advisees

Shefali Srivastava

Graduate & Fellowship Program Affiliations

• Neurosciences
• Psychiatry and Behavioral Science

Internet Links

• Stanford Bipolar Disorders Clinic

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information

Current Research Interests

Dr. Ketter has done extensive research into the etiology, phenomenology, and treatment of bipolar disorder. His etiologic research has focused on the use of brain imaging methods such as magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and positron emission tomography (PET) to better understand the neurobiology of mood disorders and to explore the possibility of using these techniques to more effectively target treatments for patients with bipolar disorder. His phenomenologic research has focused on the development and course of bipolar disorder in late adolescence and young adulthood, particularly in college students, and links between creativity, temperament, and mood disorders. His research into treatment has involved clinical trials of novel medications and combinations of medications in the treatment of bipolar disorder, with an emphasis on the use of anticonvulsants.

Clinical Trials

• Bipolar CHOICE Recruiting
• Short Term Rescue Study of Olanzapine No longer recruiting

Publications

• Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Carlson BX, Ketter TA, Sun W, Timko K, McQuade RD, Sanchez R, Vester-Blokland E, Marcus R. Bipolar Disord. 2012; 14 (1): 41-53
• Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients. Srivastava S, Wang PW, Hill SJ, Childers ME, Keller KL, Ketter TA. J Psychiatr Res. 2012
• Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bowden CL, Perlis RH, Thase ME, Ketter TA, Ostacher MM, Calabrese JR, Reilly-Harrington NA, Gonzalez JM, Singh V, Nierenberg AA, Sachs GS. CNS Neurosci Ther. 2011
• Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Srivastava S, Ketter TA. Clin Ther. 2011; 33 (12): B40-8
• Gender-specific lipid profiles in patients with bipolar disorder. Vemuri M, Kenna HA, Wang PW, Ketter TA, Rasgon NL. J Psychiatr Res. 2011; 45 (8): 1036-41